VALIRX PLC — Director's Dealing 2025

Mar 21, 2025

National Storage Mechanism | Additional information

RNS Number : 6998B

ValiRx PLC

21 March 2025

ValiRx PLC

("ValiRx" or the "Company")

Director Disclosure Update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, issues the following disclosure in relation to Martin Gouldstone, Chairman of the Company pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Oncimmune Holdings PLC, a company which Martin Gouldstone is a Director, recently announced its intention to appoint administrators.

There is nothing further to disclose in respect of Schedule 2(g) of the AIM Rules for Companies.

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video 
 summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor 
 hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/oPB60P
ValiRx plc Dr Mark Eccleston, CEO	Tel: +44 115 784 0025 www.valirx.com [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Shard Capital Partners LLP (Sole Broker) Damon Heath	Tel: +44 (0) 20 7186 9000
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	+44 (0) 115 787 0206 www.vformation.biz [email protected] [email protected]

Subscribe to our news alert service: https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBBGDXSGDDGUB